Arexvy Vaccine for RSV Prevention

EMA Accepts GSK's Expansion Application

Upcoming News Article: Impactful Storytelling

In a groundbreaking move, the European Medicines Agency (EMA) has accepted GSK's application to expand the use of Arexvy, an adjuvanted respiratory syncytial virus (RSV) vaccine. Arexvy, now authorized throughout the EU, is a significant step forward in protecting people aged 60 and over against RSV, a common and potentially deadly virus that causes lower respiratory tract disease (LRTD).

RSV is a highly contagious virus that infects nearly everyone by the age of two. While most people recover without complications, RSV can be particularly severe in older adults, leading to pneumonia, bronchitis, and even hospitalization. Arexvy is designed to strengthen the immune response to RSV, helping to prevent LRTD caused by the virus.

The upcoming news article will delve deeper into the significance of Arexvy's expanded use and its impact on public health. Stay tuned for further updates and insightful commentary on this groundbreaking development.